Zoetis Inc (NYSE:ZTS) – Analysts at William Blair boosted their FY2019 EPS estimates for shares of Zoetis in a research note issued to investors on Friday, November 8th. William Blair analyst J. Kreger now expects that the company will post earnings of $3.60 per share for the year, up from their prior forecast of $3.56. William Blair also issued estimates for Zoetis’ Q4 2019 earnings at $0.87 EPS, Q2 2020 earnings at $0.98 EPS, Q3 2020 earnings at $1.02 EPS, Q4 2020 earnings at $1.05 EPS, FY2020 earnings at $3.95 EPS, FY2021 earnings at $4.40 EPS, FY2022 earnings at $4.91 EPS and FY2023 earnings at $5.46 EPS.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same period last year, the firm earned $0.83 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis.
ZTS has been the topic of a number of other reports. SunTrust Banks raised their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research report on Tuesday, August 13th. Goldman Sachs Group assumed coverage on shares of Zoetis in a research report on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price target on the stock. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Barclays lifted their price objective on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley lifted their price objective on shares of Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a research report on Monday, September 30th. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $126.75.
ZTS opened at $117.20 on Monday. The company has a debt-to-equity ratio of 2.47, a current ratio of 4.39 and a quick ratio of 3.02. The company’s 50-day moving average is $124.98 and its 200 day moving average is $116.73. Zoetis has a fifty-two week low of $78.90 and a fifty-two week high of $130.20. The firm has a market capitalization of $56.14 billion, a P/E ratio of 37.44, a PEG ratio of 2.90 and a beta of 0.88.
Institutional investors and hedge funds have recently bought and sold shares of the company. JJJ Advisors Inc. purchased a new position in shares of Zoetis in the second quarter worth about $25,000. Prestige Wealth Management Group LLC purchased a new position in shares of Zoetis in the second quarter worth about $27,000. Tarbox Family Office Inc. increased its stake in shares of Zoetis by 74.4% in the third quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock worth $27,000 after purchasing an additional 93 shares in the last quarter. Altshuler Shaham Ltd increased its stake in shares of Zoetis by 198.8% in the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares in the last quarter. Finally, Tradewinds Capital Management LLC purchased a new position in shares of Zoetis in the third quarter worth about $31,000. Hedge funds and other institutional investors own 89.97% of the company’s stock.
In other Zoetis news, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $120.05, for a total value of $735,066.15. Following the sale, the executive vice president now owns 41,698 shares of the company’s stock, valued at $5,005,844.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 4,463 shares of Zoetis stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,709 shares of company stock worth $2,084,900. Insiders own 0.29% of the company’s stock.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd will be given a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Monday, October 21st. Zoetis’s dividend payout ratio is 21.09%.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.